Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3855175 | 0.79 | MEN1 (0.42) | LMNAALDH1A1PKMDPP4MEN1 | |
| SCHEMBL4535246 | 0.79 | DPP4 (0.44) | LMNAALDH1A1PKMDPP4DPP8 | |
| SCHEMBL18663582 | 0.76 | MAPT (0.43) | LMNAALDH1A1PKMDPP4DPP8 | |
| SCHEMBL1835873 | 0.76 | LMNA (0.48) | LMNAALDH1A1PKMDPP4DPP8 | |
| SCHEMBL14722640 | 0.76 | LMNA (0.40) | LMNAALDH1A1PKMDPP4DPP8 | |
| SCHEMBL18687851 | 0.76 | LMNA (0.40) | LMNAALDH1A1PKMDPP4MEN1 | |
| SCHEMBL3045187 | 0.76 | MEN1 (0.44) | LMNAALDH1A1PKMDPP4DPP8 | |
| SCHEMBL7348964 | 0.76 | DPP4 (0.42) | LMNAALDH1A1PKMDPP4DPP8 | |
| SCHEMBL5840003 | 0.76 | CSNK2A1 (0.41) | LMNAALDH1A1PKMDPP4MEN1 | |
| SCHEMBL18964905 | 0.76 | LMNA (0.40) | LMNAALDH1A1PKMDPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| EP-1943229-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007048842-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | LMNA 880/4885ALDH1A1 717/4885PKM 1789/4885 |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | LMNA 1533/4885ALDH1A1 2364/4885PKM 1153/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | LMNA 1223/4885ALDH1A1 573/4885PKM 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.